Amiodarone-Induced Thyrotoxicosis in a Patient with Multinodular Goiter

  • Serpil Salman


An old male who presented with atypical symptoms was diagnosed with thyrotoxicosis. He had multinodular goiter and was taking amiodarone (probably intermittently for a long time) for atrioventricular arrhythmias. The findings were interpreted in favor of amiodarone thyroiditis, but it was difficult to distinguish the type of amiodarone-induced thyrotoxicosis (AIT) because findings of both type 1 and 2 AIT were observed. Combined antithyroid drug (methimazole 20 mg/day) and corticosteroid (prednisolone 40 mg/day) were administered to treat both types of AIT. Normal thyroid hormone levels were found in the second week of treatment. Hepatotoxicity and decreasing platelet count developed as side effects of methimazole; therefore, the drug was stopped. Prednisolone was continued at the same dosage for 4 weeks and tapered to 6–10 mg every 4 weeks. Meanwhile, liver enzyme levels and platelet count returned to acceptable levels, but there was a risk of exacerbation. The patient was operated during the fourth month of follow-up when his cardiac problems were stable.


Amiodarone Thyrotoxicosis Multinodular goiter Methimazole Type 1 AIT Type 2 AIT 


  1. 1.
    Samuels MH, Franklyn JA. Hyperthyroidism in aging. In: De Groot LJ, Chrousos G, Dungan K, Feingold KR, Grossman A, Hershman JM, Koch C, Korbonits M, McLachlan R, New M, Purnell J, Rebar R, Singer F, Vinik A, editors. Source endotext [internet]. South Dartmouth, MA:, Inc.; 2000. Available at Scholar
  2. 2.
    Ross DS, Burch HB, Cooper DS, Greenlee MC, Laurberg P, Maia AL, et al. 2016 American Thyroid Association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid. 2016;26:1343–421.CrossRefGoogle Scholar
  3. 3.
    Zipes DP, Prystowsky EN, Heger JJ. Amiodarone: electrophysiologic actions, pharmacokinetics and clinical effects. J Am Coll Cardiol. 1984;3:1059–71.CrossRefGoogle Scholar
  4. 4.
    Vassallo P, Trohman RG. Prescribing amiodarone: an evidence-based review of clinical indications. JAMA. 2007;298:1312–22.CrossRefGoogle Scholar
  5. 5.
    Narayana SK, Woods DR, Boos CJ. Management of amiodarone-related thyroid problems. Ther Adv Endocrinol Metab. 2011;2:115–26. Scholar
  6. 6.
    Jabrocka-Hybel A, Bednarczuk T, Bartalena L, Pach D, Ruchała M, Kamiński G, et al. Amiodarone and the thyroid. Endokrynol Pol. 2015;66:176–86. Scholar
  7. 7.
    van Beeren HC, Bakker O, Wiersinga WM. Structure-function relationship of the inhibition of the 3,5,3′-triiodothyronine binding to the alpha1- and beta1-thyroid hormone receptor by amiodarone analogs. Endocrinology. 1996;137:2807–14.CrossRefGoogle Scholar
  8. 8.
    Tomisti L, Rossi G, Bartalena L, Martino E, Bogazzi F. The onset time of amiodarone-induced thyrotoxicosis (AIT) depends on AIT type. Eur J Endocrinol. 2014;171:363–8. Scholar
  9. 9.
    Czarnywojtek A, Czepczynski R, Ruchala M, Wasko R, Zgorzalewicz-Stachowiak M, Szczepanek E, et al. Radioiodine therapy in patients with amiodarone-induced thyrotoxicosis (AIT). Neuro Endocrinol Lett. 2009;30:209–14.PubMedGoogle Scholar
  10. 10.
    Pierret C, Tourtier JP, Pons Y, Merat S, Duverger V, Perrier E. Total thyroidectomy for amiodarone-associated thyrotoxicosis: should surgery always be delayed for pre-operative medical preparation? J Laryngol Otol. 2012;126:701–5. Scholar
  11. 11.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133. Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Serpil Salman
    • 1
  1. 1.Istinye University Medical Faculty, Department of Internal MedicineIstanbulTurkey

Personalised recommendations